2.Analysis of Underlying Targets and Mechanism of Ginseng Radix et Rhizoma-Astragali Radix Treatment in Lung Cancer Based on Network Pharmacology
Zheng LI ; Xie-yu ZHANG ; Zi-ang YAO ; Wei HOU
Chinese Journal of Experimental Traditional Medical Formulae 2020;26(4):207-213
Objective::To analyze the potential targets and mechanism of Ginseng Radix et Rhizoma-Astragali Radix treatment in lung cancer based on network pharmacology. Method::The Ginseng Radix et Rhizoma, Astragali Radix ingredients and target genes were screened by the traditional Chinese medicine system pharmacology database and analysis platform (TCMSP). Lung cancer-related target genes were obtained from the human gene database (GeneCards). Cytoscape was used for constructing a " drug-ingredient-target-disease" network. Protein-to-protein interaction (PPI) data was downloaded from STRING and then PPI core genes was constructed by CentiScape. Gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) enrichment analysis of key target genes was performed using R software. Result::A total of 17 Ginseng Radix et Rhizoma and 16 Astragali Radix ingredients were screened. 50 target genes of Astragali Radix and 95 target genes of Ginseng Radix et Rhizoma in the treatment of lung cancer were obtained. A " drug-ingredient-target-disease" network was constructed. 38 PPI core genes were screened using CentiScape. GO function enrichment showed that biological functions of Ginseng Radix et Rhizoma-Astragali Radix were concentrated in nuclear receptor function, transcription-related function, ubiquitination and apoptosis. KEGG pathway enrichment showed that Ginseng Radix et Rhizoma-Astragali Radix treatment in lung cancer were mainly involved in phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt), apoptosis, tumor necrosis factor (TNF) and other pathways. Conclusion::By constructing a " drug-ingredient-target-disease" network, the mechanism of Ginseng Radix et Rhizoma-Astragali Radix treatment in lung cancer was discussed from the perspective of multi-component, multi-target and multi-pathway, which provides reference for further research.
3.Research progress of nanomedical drug delivery system based on aerobic glycolytic regulation for tumor therapy
Yi-jing LI ; Sheng-nan HUANG ; Zi-ang WANG ; Wei-wei ZHI ; Xia-li ZHU
Acta Pharmaceutica Sinica 2024;59(9):2509-2518
Tumor is one of the serious problems threatening human health. There are some limitations in the delivery of commonly used tumor therapy technologies, and the therapeutic effect is not satisfactory, so new anti-tumor strategies need to be developed. The process of tumor cells using glycolysis to produce energy under aerobic conditions is called aerobic glycolysis, which is closely related to tumor growth, proliferation and metastasis, and can provide a new target spot for tumor treatment. Nano drug delivery system has been widely used in targeted tumor therapy because of its advantages of targeted drug delivery, improved anti-tumor efficacy and reduced toxic side effects. Numerous studies have shown that more and more nano drug delivery systems regulates aerobic glycolytic metabolism by targeting to potential targets such as signaling factors or reaction products of aerobic glycolytic process in tumors, and therefore enhance the anti-tumor effect. This paper reviews the application of nano drug delivery system in regulating tumor aerobic glycolysis, and provides theoretical references for realizing efficient targeted tumor therapy.
4.Research progress of nano drug delivery system based on metal-polyphenol network for the diagnosis and treatment of inflammatory diseases
Meng-jie ZHAO ; Xia-li ZHU ; Yi-jing LI ; Zi-ang WANG ; Yun-long ZHAO ; Gao-jian WEI ; Yu CHEN ; Sheng-nan HUANG
Acta Pharmaceutica Sinica 2025;60(2):323-336
Inflammatory diseases (IDs) are a general term of diseases characterized by chronic inflammation as the primary pathogenetic mechanism, which seriously affect the quality of patient′s life and cause significant social and medical burden. Current drugs for IDs include nonsteroidal anti-inflammatory drugs, corticosteroids, immunomodulators, biologics, and antioxidants, but these drugs may cause gastrointestinal side effects, induce or worsen infections, and cause non-response or intolerance. Given the outstanding performance of metal polyphenol network (MPN) in the fields of drug delivery, biomedical imaging, and catalytic therapy, its application in the diagnosis and treatment of IDs has attracted much attention and significant progress has been made. In this paper, we first provide an overview of the types of IDs and their generating mechanisms, then sort out and summarize the different forms of MPN in recent years, and finally discuss in detail the characteristics of MPN and their latest research progress in the diagnosis and treatment of IDs. This research may provide useful references for scientific research and clinical practice in the related fields.
Result Analysis
Print
Save
E-mail